Pharming (PHAR)

Company Profile

Company profile

Ticker

PHAR, PHGUF

Exchange

NASDAQ

Website

www.pharming.com

CEO

Dr. Sijmen de Vries M.B.A., M.D.

Incorporated

Netherlands

Location

Netherlands

Fiscal year end

Dec 31

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

SEC CIK

0001828316

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

PHAR stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$22.00

Low target

$14.00

High target

$30.00

Latest filings (excl ownership)

View all

6-K

Current report (foreign)

16 Dec 24

6-K

Current report (foreign)

24 Oct 24

6-K

Current report (foreign)

10 Oct 24

6-K

Current report (foreign)

26 Sep 24

6-K

Current report (foreign)

1 Aug 24

6-K

Current report (foreign)

30 May 24

6-K

Current report (foreign)

21 May 24

6-K

Current report (foreign)

15 May 24

6-K

Current report (foreign)

8 May 24

6-K

Current report (foreign)

25 Apr 24

Latest ownership filings

Financial summary

Financial statements Chart PHAR financial data

Quarter (USD)	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Pharming earnings reports.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

17 Dec 24

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

16 Dec 24

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

Pharming Announces $66.1M Cash Offer To Acquire Abliva AB, Strengthening Late-Stage Pipeline

16 Dec 24

Proposed acquisition strengthens Pharming's late-stage pipeline with a potential first-in-disease assetAbliva's lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in

European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug

11 Dec 24

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

11 Dec 24

Press releases

From Benzinga Pro

Pharming announces public cash offer to the shareholders of Abliva AB

15 Dec 24

Proposed acquisition strengthens Pharming's late-stage pipeline with a potential first-in-disease asset Abliva's lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved,

Pharming announces positive topline data in pediatric clinical trial of leniolisib

11 Dec 24

Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Data consistent with the improvements seen in the previously reported randomized

Pharming Group to participate in November investor conference

5 Nov 24

Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conference in the month of November: Jefferies

Pharming Group reports third quarter 2024 financial results and provides business update

24 Oct 24

Pharming Group to report third quarter 2024 financial results on October 24

10 Oct 24